These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 16614685)

  • 21. [Efficacy and safety of azithromycin prophylaxis of respiratory tract infections in military community].
    Guchev IA; Klochkov OI; Ivanitsa GV; Pervov IuA; Shturmina SM; Rosman SV
    Antibiot Khimioter; 2004; 49(8-9):34-5, 37-42. PubMed ID: 15727144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia.
    Lynch III JP; Martinez FJ
    Clin Infect Dis; 2002 Mar; 34 Suppl 1():S27-46. PubMed ID: 11810608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A critical assessment of published guidelines and other decision-support systems for the antibiotic treatment of community-acquired respiratory tract infections.
    Finch RG; Low DE
    Clin Microbiol Infect; 2002; 8 Suppl 2():69-91. PubMed ID: 12427208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4.
    Jenkins SG; Brown SD; Farrell DJ
    Ann Clin Microbiol Antimicrob; 2008 Jan; 7():1. PubMed ID: 18190701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antimicrobial resistance with bacterial causes of community-acquired respiratory tract infections in the United States.
    Doern GV
    Treat Respir Med; 2005; 4 Suppl 1():1-4. PubMed ID: 15846150
    [No Abstract]   [Full Text] [Related]  

  • 26. [Discussions on PRSP and BLNAR].
    Tajima T; Meguro H; Akita H; Iwata T
    Jpn J Antibiot; 2001 May; 54 Suppl B():103; discussion 104-6. PubMed ID: 12638161
    [No Abstract]   [Full Text] [Related]  

  • 27. Microbiological and pharmacodynamic considerations in the treatment of infection due to antimicrobial-resistant Streptococcus pneumoniae.
    Appelbaum PC
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S29-34. PubMed ID: 10984325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Worldwide guidelines for respiratory tract infections: community-acquired pneumonia.
    Dalhoff K
    Int J Antimicrob Agents; 2001; 18 Suppl 1():S39-44. PubMed ID: 11574194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and public health implications of macrolide-resistant Streptococcus pneumoniae.
    Moellering RC; Craig W; Edmond M; Farrell DJ; Ferraro MJ; File TM; Klein J; Lonks J; Metlay JP; Sahm D; Talbot GH;
    J Chemother; 2002 Jul; 14 Suppl 3():42-56. PubMed ID: 12418560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gemifloxacin: survival of the fittest.
    Mandell L
    J Antimicrob Chemother; 2000 Jul; 46 Suppl T1():33-7. PubMed ID: 10997597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Telithromycin in the treatment of pneumococcal community-acquired respiratory tract infections: a review.
    Fogarty CM; Buchanan P; Aubier M; Baz M; van Rensburg D; Rangaraju M; Nusrat R
    Int J Infect Dis; 2006 Mar; 10(2):136-47. PubMed ID: 16183318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Susceptibility of streptococcus pneumoniae to fluoroquinolones and macrolides in upper respiratory tract infections.
    Mykhalko YO; Duhovych TV; Kish PP
    Wiad Lek; 2017; 70(2):224-226. PubMed ID: 28511165
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens--findings of the Alexander Project 1992-1996.
    Felmingham D; Washington J
    J Chemother; 1999 Feb; 11 Suppl 1():5-21. PubMed ID: 10207769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Vaccination against pneumococcal infection in adults].
    Viejo JL
    Rev Esp Quimioter; 2009 Nov; 22 Suppl 1():26-8. PubMed ID: 20084346
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical management of respiratory tract infections in the community: experience with telithromycin.
    Quintiliani R
    Infection; 2001 Dec; 29 Suppl 2():16-22. PubMed ID: 11785852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Principles of appropriate antibiotic use.
    Niederman MS
    Int J Antimicrob Agents; 2005 Dec; 26 Suppl 3():S170-5. PubMed ID: 16543079
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pooled analysis of telithromycin in the treatment of community-acquired respiratory tract infections in adults.
    Carbon C
    Infection; 2003 Oct; 31(5):308-17. PubMed ID: 14556055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Antibacterial therapy of pneumococcal infections caused by drug resistant microorganisms].
    Sidorenko SV
    Antibiot Khimioter; 2002; 47(7):31-7. PubMed ID: 12516194
    [No Abstract]   [Full Text] [Related]  

  • 39. Macrolide Resistance in
    Schroeder MR; Stephens DS
    Front Cell Infect Microbiol; 2016; 6():98. PubMed ID: 27709102
    [No Abstract]   [Full Text] [Related]  

  • 40. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
    White AR; Kaye C; Poupard J; Pypstra R; Woodnutt G; Wynne B
    J Antimicrob Chemother; 2004 Jan; 53 Suppl 1():i3-20. PubMed ID: 14726431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.